Most Read Articles
29 Nov 2019
Metformin Extended Release 500 mg,750 mg, and 1000 mg
Elvira Manzano, Roshini Claire Anthony, 01 Oct 2019

The European Society of Cardiology (ESC) has released five new guidelines at the ESC Congress 2019, recommending an even lower LDL-C* target in patients at very high risk for cardiovascular disease (CVD), and the use of SGLT2** inhibitors and GLP-1*** receptor agonists as first-line treatments in those with diabetes to reduce their CVD risk.

Roshini Claire Anthony, 16 Dec 2016

Five years of extended therapy with the aromatase inhibitor (AI) letrozole did not improve survival in postmenopausal breast cancer patients, according to findings of the NRG Oncology/NSABP B-42 trial presented at the San Antonio Breast Cancer Symposium (SABCS 2016) held in Texas, US. 

Jackey Suen, 21 Dec 2016

Adding everolimus to fulvestrant in second-line treatment of hormone receptor (HR)-positive, HER2-negative advanced breast cancer improves progression-free survival (PFS) by 40 percent, the phase II PrECOG 0102 study has shown. [SABCS 2016, abstract S1-02]

Add-on tacrolimus provides short-term survival gains in PM/DM-interstitial pneumonia

21 Oct 2019

Initial treatment with tacrolimus and glucocorticoids (GCs) appears to improve short-term mortality in polymyositis (PM)/dermatomyositis (DM)-interstitial pneumonia patients, according to a recent study.

A total of 25 patients (mean age, 55.4 years; 76 percent female) received initial combination treatment with tacrolimus (0.075 mg/kg/day, adjusted for the target whole-blood trough levels between 5 and 10 ng/ml) and glucocorticoids (0.6–1.0 mg/kg/day of prednisolone followed by a slow taper) for 52 weeks.

The primary outcome of overall survival at 52 weeks was 88.0 percent (95 percent CI, 67.3–96.0 percent). Progression-free survival rate was 76.4 percent (51.8–89.5 percent).

Whole-blood tacrolimus trough levels were preserved within the targeted range of 5 and 10 ng/ml throughout the study period (average, 6.6 ng/ml), with an average daily dose of 3.81 mg/day (0.072 mg/kg/day).

The safety profile of the combination treatment was consistent with the known adverse event (AE) profile of tacrolimus and high-dose GCs individually. A total of 11 patients (44 percent) developed serious adverse events, which included four opportunistic infections.

In total, there were 475 AEs recorded, of which 357 (75.2 percent) were deemed possibly, probably or definitely associated with tacrolimus or GCs by treating physicians.

The current prospective clinical investigation was the first to be conducted according to the Good Clinical Practice Guideline of the International Conference on Harmonization for the treatment of PM/DM-interstitial pneumonia.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacist - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
29 Nov 2019
Metformin Extended Release 500 mg,750 mg, and 1000 mg
Elvira Manzano, Roshini Claire Anthony, 01 Oct 2019

The European Society of Cardiology (ESC) has released five new guidelines at the ESC Congress 2019, recommending an even lower LDL-C* target in patients at very high risk for cardiovascular disease (CVD), and the use of SGLT2** inhibitors and GLP-1*** receptor agonists as first-line treatments in those with diabetes to reduce their CVD risk.

Roshini Claire Anthony, 16 Dec 2016

Five years of extended therapy with the aromatase inhibitor (AI) letrozole did not improve survival in postmenopausal breast cancer patients, according to findings of the NRG Oncology/NSABP B-42 trial presented at the San Antonio Breast Cancer Symposium (SABCS 2016) held in Texas, US. 

Jackey Suen, 21 Dec 2016

Adding everolimus to fulvestrant in second-line treatment of hormone receptor (HR)-positive, HER2-negative advanced breast cancer improves progression-free survival (PFS) by 40 percent, the phase II PrECOG 0102 study has shown. [SABCS 2016, abstract S1-02]